Adenoviral infectivity of exfoliated viable cells in urine: Implications for the detection of bladder cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Murali, Anuradha ^a   Kasman, Laura ^a   Voelkel Johnson, Christina ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ARTICLE; BLADDER CANCER; CANCER CELL; CELL; CONTROLLED STUDY; CYTOMEGALOVIRUS; EXFOLIATED CELL; EXPLANT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PROMOTER REGION; URINALYSIS; URINE SEDIMENT; ADENOVIRUS; BLADDER TUMOR; CELL LINE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; PHYSIOLOGY; REPORTER GENE; TRANSGENE; TUMOR CELL LINE; URINE;

ADENOVIRIDAE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC VECTORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROMOTER REGIONS, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES; URINARY BLADDER NEOPLASMS; URINE;

EID: 79955792183     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-168     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come?. CA Cancer J Clin 2010, 60(4):244-272. 10.3322/caac.20077, 20566675.
3. Elias K, Svatek RS, Gupta S, Ho R, Lotan Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer 116(12):2954-2959.
4. Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol
5. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002, 167(1):75-79. 10.1016/S0022-5347(05)65386-4, 11743279.
6. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009, 16(3):234-243. 10.1111/j.1442-2042.2008.02225.x, 19298346.
7. Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 28(3):399-404.
8. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001, 285(3):324-328. 10.1001/jama.285.3.324, 11176843.
9. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004, 11(4):256-262. 10.1038/sj.cgt.7700679, 15017380.
10. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, Somji S, Nath J, Sens DA. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 2001, 109(8):801-808. 10.1289/ehp.01109801, 1240407, 11564615.
11. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277(5):3247-3257. 10.1074/jbc.M106643200, 11714700.
12. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2007, 2(5):1236-1247. 10.1038/nprot.2007.135, 17546019.
13. Kulkarni GS, Alibhai SM, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Bayoumi AM. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 2009, 115(23):5450-5459. 10.1002/cncr.24634, 19685529.
14. Mitra AP. Urine cytologic analysis: special techniques for bladder cancer detection. Connection 2010, 14:169-177. Kumar GL, Kiernan JA.
15. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16(11):3011-3018.
16. Jacobs BL, Lee CT, Montie JE. Bladder Cancer in 2010: How Far have We Come?. CA Cancer J Clin
17. Belik R, Follmann W, Degen GH, Roos PH, Blaszkewicz M, Knopf HJ, Golka K. Improvements in culturing exfoliated urothelial cells in vitro from human urine. J Toxicol Environ Health A 2008, 71(13-14):923-929.
18. Okuno H, Kakehi Y, Ozdemir E, Terachi T, Okada Y, Yoshida O. Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers. J Urol 1997, 158(5):1996-1999. 10.1016/S0022-5347(01)64200-9, 9334656.
19. Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006, 104(4):583-592. 10.3171/jns.2006.104.4.583, 16619663.
20. Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol 2009, 34(3):729-742. 2790828, 19212678.
21. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 2006, 175(6):2312-2316. 10.1016/S0022-5347(06)00254-0, 16697865.
22. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004, 92(4):656-663. 10.1002/jcb.20140, 15211564.
23. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005, 92(1):120-124. 10.1038/sj.bjc.6602314, 2361728, 15611790.
24. Weikert S, Schrader M, Krause H, Schulze W, Muller M, Miller K. The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes. Cancer Lett 2005, 223(2):331-337. 10.1016/j.canlet.2004.10.038, 15896468.